

**Publikationen 2015**  
**Klin. Abt. für Hämatologie und Hämostaseologie**  
**Univ.-Klinik Innere Medizin I**

1. Altorjay Á, Szabó É, Boda Z, Kramer L, Ngo LY, Engl W, Firth CL, Ahlstrom ER, Belmont DM, Pabinger I. An international, multicenter, prospective study of a prothrombin complex concentrate, Prothromplex Total®, in anticoagulant reversal. *Thromb Res* 2015; 135(3): 485-91. **2,447**
2. Arock M, Akin C, Hermine O, Valent P. Current treatment options in patients with mastocytosis: status in 2015 and future perspectives. *Eur J Haematol* 2015; 94(6): 474-90. *Review* **2,066**
3. Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L, Kristensen TK, Kluin-Nelemans HC, Hermine O, Dubreuil P, Sperr WR, Hartmann K, Gotlib J, Cross NC, Haferlach T, Garcia-Montero A, Orfao A, Schwaab J, Triggiani M, Horny HP, Metcalfe DD, Reiter A, Valent P. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. *Leukemia* 2015; 29(6): 1223-32. *Review* **10,431**
4. Ay C, Pabinger I. VTE risk assessment in cancer. Who needs prophylaxis and who does not? *Hamostaseologie*. 2015; 35(4): 319-24. **1,602**
5. Ay C, Posch F, Kaider A, Zielinski C, Pabinger I. Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality. *J Thromb Haemost* 2015; 13(3): 390-7. **5,720**
6. Banerjee S, Resch Y, Chen KW, Swoboda I, Focke-Tejkl M, Blatt K, Novak N, Wickman M, van Hage M, Ferrara R, Mari A, Purohit A, Pauli G, Sibanda EN, Ndlovu P, Thomas WR, Krzyzanski V, Tacke S, Malkus U, Valent P, Valenta R, Vrtala S. Der p 11 is a major allergen for house dust mite-allergic patients suffering from atopic dermatitis. *J Invest Dermatol* 2015; 135(1): 102-9. **7,216**
7. Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Finazzi G, Carobbio A, Thiele J, Passamonti F, Falcone C, Tefferi A. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. *Blood Cancer J* 2015; 5: e369. *Letter to the Editor* **3,467**
8. Barbui T, Vannucchi AM, Carobbio A, Thiele J, Rumi E, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Pieri L, Pardanani A, Passamonti F, Finazzi G, Tefferi A. Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis. *Am J Hematol* 2015; 90(5): 434-7. **3,798**

9. Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Harrison C, Hehlmann R, Hermouet S, Kiladjian JJ, Kröger N, Mesa R, Mc Mullin MF, Pardanani A, Passamonti F, Samuelsson J, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tognoni G, Barbui T. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). *Leukemia* 2015; 29(1): 20-6. *Review* **10,431**
  
10. Bianconi D, Schuler A, Pausz C, Geroldinger A, Kaider A, Lenz HJ, Kornek G, Scheithauer W, Zielinski CC, Pabinger I, Ay C, Prager GW. Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients. *Thromb Res* 2015; 136(5): 865-9 **2,447**
  
11. Blatt K, Cerny-Reiterer S, Schwaab J, Sotlar K, Eisenwort G, Stefanzi G, Hoermann G, Mayerhofer M, Schneeweiss M, Knapp S, Rülcke T, Hadzijusufovic E, Bauer K, Smiljkovic D, Willmann M, Reiter A, Horny HP, Valent P. Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis. *Blood* 2015; 126(26): 2832-41. **10,452**
  
12. Bojic M, Berghoff AS, Troch M, Agis H, Sperr WR, Widhalm G, Wöhrer A, Kalhs P, Preusser M, Rabitsch W. Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review. *Eur J Haematol* 2015; 95(1): 75-82. **2,066**
  
13. Braulke F, Müller-Thomas C, Götze K, Platzbecker U, Germing U, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Hildebrandt B, Aul C, Stauder R, Valent P, Fonatsch C, Bacher U, Trümper L, Haase D, Schanz J. Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group. *Genes Chromosomes Cancer* 2015; 54(12): 809-17. **4,041**
  
14. Braulke F, Platzbecker U, Müller-Thomas C, Götze K, Germing U, Brümmendorf TH, Nolte F, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Mallo M, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Shirneshan K, Aul C, Stauder R, Sperr WR, Valent P, Fonatsch C, Trümper L, Haase D, Schanz J. Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group. *Haematologica* 2015; 100(2): 205-13. **5,814**
  
15. Brunhofer-Bolzer G, Le T, Dyckmanns N, Knaus HA, Pausz C, Freund P, Jäger U, Erker T, Vanura K. SAR-guided development and characterization of a potent antitumor compound toward B-cell neoplasms with no detectable cytotoxicity toward healthy cells. *J Med Chem* 2015; 58(3): 1244-53. **5,447**
  
16. Burgstaller S, Bettelheim P, Krieger O, Machherndl-Spandl S, Nösslinger T, Pleyer L, Sill H, Sperr WR, Stauder R, Valent P, Pfeilstöcker M. 10th anniversary of the Austrian MDS Platform: aims and ongoing projects. *Wien Klin Wochenschr* 2015; 127(1-2): 12-5. *Review* **0,836**

17. Cerny-Reiterer S, Rabenhorst A, Stefanzi G, Herndlhofer S, Hoermann G, Müllauer L, Baumgartner S, Beham-Schmid C, Sperr WR, Mannhalter C, Sill H, Linkesch W, Arock M, Hartmann K, Valent P. Long-term treatment with Imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia. *Oncotarget* 2015; 6(5): 3071-84. **6,359**
18. Chowdary P, Lethagen S, Friedrich U, Brand B, Hay C, Abdul Karim F, Klamroth R, Knoebl P, Laffan M, Mahlangu J, Miesbach W, Dalsgaard Nielsen J, Martín-Salces M, Angchaisuksiri P. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. *J Thromb Haemost* 2015; 13(5): 743-54. **5,720**
19. Della Porta MG, Tuechler H, Malcovati L, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL, Cazzola M. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). *Leukemia* 2015; 29(7): 1502-13. **10,431**
20. Desterke C, Martinaud C, Guerton B, Pieri L, Bogani C, Clay D, Torossian F, Lataillade JJ, Hasselbach HC, Gisslinger H, Demory JL, Dupriez B, Boucheix C, Rubinstein E, Amsellem S, Vannucchi AM, Le Bousse-Kerdilès MC. Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis. *Haematologica* 2015; 100(6): 757-67. **5,814**
21. Di Minno G, Zotz RB, d'Oiron R, Bindslev N, Di Minno MN, Poon MC; Glanzmann Thrombasthenia Registry Investigators (Kyrle PA). The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia. *Haematologica* 2015; 100(8): 1031-7. **5,814**
22. Eckhardt CL, Loomans JJ, van Velzen AS, Peters M, Mauser-Bunschoten EP, Schwaab R, Mazzucconi MG, Tagliaferri A, Siegmund B, Reitter-Pfoertner SE, van der Bom JG, Fijnvandraat K; INSIGHT Study Group. Inhibitor development and mortality in non-severe hemophilia A. *J Thromb Haemost* 2015; 13(7): 1217-25. **5,720**
23. Fabian E, Eisner F, Pabinger I, Viertler C, Regauer S, Lueger A, Neumeister P, Weiss EC, Schöll W, Lang U, Prüller F, Krejs GJ. Clinical-Pathological Conference Series from the Medical University of Graz Case No 155: 26-year-old woman in third trimester of pregnancy with epigastric pain and thrombocytopenia. *Wien Klin Wochenschr* 2015; 127(17-18): 707-14. *Clinical Conference* **0,836**
24. Fischer K, Iorio A, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Gilman EA, Makris M; EUHASS Participants (Kyrle PA). Inhibitor development in non-severe haemophilia across Europe. *Thromb Haemost* 2015; 114(4): 670-5. **4,984**

25. Focke-Tejkl M, Weber M, Niespodziana K, Neubauer A, Huber H, Henning R, Stegellner G, Maderegger B, Hauer M, Stolz F, Niederberger V, Marth K, Eckl-Dorna J, Weiss R, Thalhamer J, Blatt K, Valent P, Valenta R. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. *J Allergy Clin Immunol* 2015; 135(5): 1207-7. **11,476**
26. Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman MV, Bergqvist D, Turpie AG, Ortel TL, Spyropoulos AC, Pabinger I, Kakkar AK. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. *J Thromb Haemost* 2015; 13(6): 1028-35. **5,720**
27. Gebhart J, Laczkovics C, Posch F, Ay C, Reitter-Pfoertner SE, Haslacher H, Muszbek L, Wolberg AS, Pabinger I. Plasma clot properties in patients with a mild-to-moderate bleeding tendency of unknown cause. *Ann Hematol* 2015; 94(8): 1301-10. **2,634**
28. Gebhart J, Posch F, Koder S, Perkmann T, Quehenberger P, Zoghiami C, Ay C, Pabinger I. Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). *Blood* 2015; 125(22): 3477-83. **10,452**
29. Geissler K, Jäger E, Öhler L, Gisslinger H, Jäger U, Lechner K. Interleukin-10 inhibits autonomous myelopoiesis in patients with myelofibrosis. *Eur J Haematol* 2015; 95(3): 239-43. **2,066**
30. Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Them NC, Kadlecova P, Klade C, Greil R. Ropeginterferon alfa-2b, a novel IFN $\alpha$ -2b, induces high response rates with low toxicity in patients with polycythemia vera. *Blood* 2015; 126(15): 1762-9. **10,452**
31. Griesshammer M, Gisslinger H, Mesa R. Current and future treatment options for polycythemia vera. *Ann Hematol* 2015; 94(6): 901-10. *Review* **2,634**
32. Grunt TW, Hebar A, Laffer S, Wagner R, Peter B, Herrmann H, Graf A, Bilban M, Posch M, Hoermann G, Mayerhofer M, Eisenwort G, Zielinski CC, Selzer E, Valent P. Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells. *Am J Cancer Res* 2015; 5(2): 560-74. **4,165**
33. Harutyunyan AS, Jäger R, Chen D, Berg T, Rumi E, Gisslinger B, Pietra D, Gisslinger H, Cazzola M, Kralovics R. Allelic imbalance in CALR somatic mutagenesis. *Leukemia* 2015; 29(6): 1431-5. *Letter to the Editor* **10,431**
34. Hermann A, Riss K, Schellongowski P, Bojic A, Wohlfarth P, Robak O, Sperr WR, Staudinger T. A novel pump-driven veno-venous gas exchange system during extracorporeal CO<sub>2</sub>-removal. *Intensive Care Med* 2015; 41(10): 1773-80. **7,214**

35. Heuser M, Meggendorfer M, Cruz MM, Fabisch J, Klesse S, Köhler L, Göhring G, Ganster C, Shirneshan K, Gutermuth A, Cerny-Reiterer S, Krönke J, Panagiota V, Haferlach C, Koenecke C, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Ehrlich S, Stamer K, Döhner K, Valent P, Schlegelberger B, Kroeger N, Ganser A, Haase D, Haferlach T, Thol F. Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q. *Leukemia* 2015; 29(9): 1942-5. *Letter to the Editor* **10,431**
36. Hisada Y, Geddings JE, Ay C, Mackman N. Venous thrombosis and cancer: from mouse models to clinical trials. *J Thromb Haemost.* 2015; 13(8): 1372-82. *Review* **5,720**
37. Hoermann G, Greiner G, Valent P. Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms. *Mediators Inflamm* 2015; 2015: 869242. *Review* **3,236**
38. Hofbauer CJ, Whelan SF, Hirschler M, Allacher P, Horling FM, Lawo JP, Oldenburg J, Tiede A, Male C, Windyga J, Greinacher A, Knöbl PN, Schrenk G, Koehn J, Scheiflinger F, Reipert BM. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. *Blood* 2015; 125(7): 1180-8. **10,452**
39. Jaeger U, Praxmarer M, Greil R; AGMT-NHL13 investigators. Response to comment by P. Vassilakopoulos and colleagues. *Haematologica* 2015; 100(11): e482. *Comment* **5,814**
40. Jaeger U, Trneny M, Melzer H, Praxmarer M, Nawarawong W, Ben Yehuda D, Goldstein D, Mihaljevic B, Ilhan O, Ballova V, Hedenus M, Hsiao LT, Au WY, Burgstaller S, Weidinger G, Keil F, Dittrich C, Skrabs C, Klingler A, Chott A, Fridrik MA, Greil R; AGMT-NHL13 Investigators. Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. *Haematologica* 2015; 100(7): 955-63. **5,814**
41. Jawhar M, Schwaab J, Schnittger S, Sotlar K, Horny HP, Metzgeroth G, Müller N, Schneider S, Naumann N, Walz C, Haferlach T, Valent P, Hofmann WK, Cross NC, Fabarius A, Reiter A. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. *Leukemia* 2015; 29(5): 1115-22. **10,431**
42. Karmacharya P, Donato AA, Aryal MR, Pathak R, Goonewardene M, Valent P. All systems red. *Am J Hematol* 2015; 90(4): 356-60. *Case report* **3,798**
43. Kepa S, Horvath B, Reitter-Pfoertner S, Schemper M, Quehenberger P, Grundbichler M, Heistingner M, Neumeister P, Mannhalter C, Pabinger I. Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A. *Haemophilia* 2015; 21(3): 343-50. **2,603**
44. Kessler CM, Knöbl P. Acquired haemophilia: an overview for clinical practice. *Eur J Haematol* 2015; 95 Suppl 81: 36-44. *Review* **2,066**
45. Khorana AA, Zwicker JI, Connolly GC, Pabinger I. Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH: reply. *J Thromb Haemost* 2015; 13(2): 325-6. *Letter to the Editor* **5,720**

46. Knöbl P. NET untangled in TMA? *J Thromb Haemost* 2015; 13(5): 729-31. *Editorial* **5,720**
47. Koneczny I, Schulenburg A, Hudec X, Knöfler M, Holzmann K, Piazza G, Reynolds R, Valent P, Marian B. Autocrine fibroblast growth factor 18 signaling mediates Wnt-dependent stimulation of CD44-positive human colorectal adenoma cells. *Mol Carcinog* 2015; 54(9): 789-99. **4,808**
48. Königsbrügge O, Quehenberger P, Belik S, Weigel G, Seger C, Griesmacher A, Pabinger I, Ay C. Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban. *Ann Hematol* 2015; 94(9): 1463-71. **2,634**
49. Krauth MT, Alpermann T, Bacher U, Eder C, Dicker F, Ulke M, Kuznia S, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S. WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups. *Leukemia* 2015; 29(3): 660-7. **10,431**
50. Lamm W, Wohlfarth P, Bojic M, Schörghofer C, Drach J, Gisslinger H, Worel N, Schiefer A, Schulenburg A, Agis H, Kalhs P, Greinix HT, Schellongowski P, Rabitsch W. Outcome in Multiple Myeloma Patients Eligible for Stem Cell Transplantation: A Single-Center Experience. *Oncology* 2015; 89(4): 196-204. **2,422**
51. Linhart B, Focke-Tejkl M, Weber M, Narayanan M, Neubauer A, Mayrhofer H, Blatt K, Lupinek C, Valent P, Valenta R. Molecular evolution of hypoallergenic hybrid proteins for vaccination against grass pollen allergy. *J Immunol* 2015; 194(8): 4008-18. **4,922**
52. Lip GY, Rushton-Smith SK, Goldhaber SZ, Fitzmaurice DA, Mantovani LG, Goto S, Haas S, Bassand JP, Camm AJ, Ambrosio G, Janský P, Al Mahmeed W, Oh S, van Eickels M, Raatikainen P, Steffel J, Oto A, Kayani G, Accetta G, Kakkar AK; GARFIELD-AF Investigators (Eichinger S). Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. *Circ Cardiovasc Qual Outcomes* 2015; 8 (2 Suppl 1): S12-20. **5,906**
53. Ludwig H, Evstatiev R, Kornek G, Apro M, Bauernhofer T, Buxhofer-Ausch V, Fridrik M, Geissler D, Geissler K, Gisslinger H, Koller E, Kopetzky G, Lang A, Rumpold H, Steurer M, Kamali H, Link H. Erratum to: Iron metabolism and iron supplementation in cancer patients. *Wien Klin Wochenschr* 2015; 127: 920-1. *Erratum* **0,836**
54. Ludwig H, Evstatiev R, Kornek G, Apro M, Bauernhofer T, Buxhofer-Ausch V, Fridrik M, Geissler D, Geissler K, Gisslinger H, Koller E, Kopetzky G, Lang A, Rumpold H, Steurer M, Kamali H, Link H. Iron metabolism and iron supplementation in cancer patients. *Wien Klin Wochenschr* 2015; 127: 907-19. *Review* **0,836**
55. Madritsch C, Eckl-Dorna J, Blatt K, Ellinger I, Kundi M, Niederberger V, Valent P, Valenta R, Flicker S. Antibody conjugates bispecific for intercellular adhesion molecule 1 and allergen prevent migration of allergens through respiratory epithelial cell layers. *J Allergy Clin Immunol* 2015; 136(2): 490-3. *Letter to the Editor* **11,476**

56. Marcucci M, Iorio A, Douketis JD, Eichinger S, Tosetto A, Baglin T, Cushman M, Palareti G, Poli D, Tait RC, Kyrle PA. Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. *J Thromb Haemost* 2015; 13(5): 775-81. **5,720**
57. Mayerhoefer ME, Karanikas G, Kletter K, Prosch H, Kiesewetter B, Skrabs C, Porpaczy E, Weber M, Knogler T, Sillaber C, Jaeger U, Simonitsch-Klupp I, Ubl P, Müllauer L, Dolak W, Lukas J, Raderer M. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients. *Clin Cancer Res* 2015; 21(11): 2506-13. **8,722**
58. McMullin MF, Harrison CN, Niederwieser D, Demuynck H, Jäkel N, Gopalakrishna P, McQuitty M, Stalbovskaya V, Recher C, Theunissen K, Gisslinger H, Kiladjian JJ, Al-Ali HK. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. *Exp Hematol Oncol* 2015; 4: 26. -
59. Merkel O, Hamacher F, Griessl R, Grabner L, Schiefer AI, Prutsch N, Baer C, Egger G, Schleder M, Krenn PW, Hartmann TN, Simonitsch-Klupp I, Plass C, Staber PB, Moriggl R, Turner SD, Greil R, Kenner L. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. *J Pathol* 2015; 236(4): 445-56. **7,429**
60. Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, Schuh A, Norin S, Geisler C, Hillmen P, Doubek M, Trněný M, Obrtlíková P, Laurenti L, Stilgenbauer S, Smolej L, Ghia P, Cymbalista F, Jaeger U, Stamatopoulos K, Stavroyianni N, Carrington P, Zouabi H, Leblond V, Gomez-Garcia JC, Rubio M, Marasca R, Musuraca G, Rigacci L, Farina L, Paolini R, Pospisilova S, Kimby E, Bradley C, Montserrat E. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. *Haematologica* 2015; 100(4): 511-6. **5,814**
61. Niklas N, Hafenscher J, Barna A, Wiesinger K, Pröll J, Dreiseitl S, Preuner-Stix S, Valent P, Lion T, Gabriel C. cFinder: definition and quantification of multiple haplotypes in a mixed sample. *BMC Res Notes* 2015; 8: 422. -
62. Obut F, Randall N, Young JA, Valent P, Ustun C. Dasatinib-induced immunosuppression and recurrent respiratory tract infections. *Leuk Lymphoma* 2015; 56(8): 2484-5. *Short communication* **2,891**
63. Pabinger I, Ay C, Dunkler D, Thaler J, Reitter EM, Marosi C, Zielinski C, Mannhalter C. Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the Vienna Cancer And Thrombosis Study (CATS). *J Thromb Haemost* 2015; 13(1): 17-22 **5,720**
64. Pabinger I, Heisteringer M, Muntean W, Reitter-Pfoertner SE, Rosenlechner S, Schindl T, Schuster G, Streif W, Thom K, Male C. [Treatment of haemophilia in Austria]. *Wien Klin Wochenschr* 2015; 127 Suppl 3: 115-30. *Consensus report* **0,836**

65. Panotopoulos J, Posch F, Alici B, Funovics P, Stihsen C, Amann G, Brodowicz T, Windhager R, Ay C. Hemoglobin, alkaline phosphatase, and C-reactive protein predict the outcome in patients with liposarcoma. *J Orthop Res* 2015; 33(5): 765-70. **2,986**
66. Pavo N, Raderer M, Hülsmann M, Neuhold S, Adlbrecht C, Strunk G, Goliasch G, Gisslinger H, Steger GG, Hejna M, Köstler W, Zöchbauer-Müller S, Marosi C, Kornek G, Auerbach L, Schneider S, Parschalk B, Scheithauer W, Pirker R, Drach J, Zielinski C, Pacher R. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. *Heart* 2015; 101(23): 1874-80. **5,595**
67. Poepl W, Lagler H, Raderer M, Sperr WR, Zielinski C, Herkner H, Burgmann H. Influenza vaccination perception and coverage among patients with malignant disease. *Vaccine* 2015; 33(14): 1682-7. **3,624**
68. Poon MC, d'Oiron R, Zotz RB, Bindslev N, Di Minno MN, Di Minno G; Glanzmann Thrombasthenia Registry Investigators (Kyrle PA). The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention. *Haematologica* 2015; 100(8): 1038-44. **5,814**
69. Posch F, Königsbrügge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. *Thromb Res* 2015; 136(3): 582-9. **2,447**
70. Radonjic-Hoesli S, Valent P, Klion AD, Wechsler ME, Simon HU. Novel targeted therapies for eosinophil-associated diseases and allergy. *Annu Rev Pharmacol Toxicol* 2015; 55: 633-56. *Review* **18,365**
71. Rathert P, Roth M, Neumann T, Muerdter F, Roe JS, Muhar M, Deswal S, Cerny-Reiterer S, Peter B, Jude J, Hoffmann T, Boryń ŁM, Axelsson E, Schweifer N, Tontsch-Grunt U, Dow LE, Gianni D, Pearson M, Valent P, Stark A, Kraut N, Vakoc CR, Zuber J. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. *Nature* 2015; 525(7570): 543-7. *Letter* **41,456**
72. Roach RE, Lijfering WM, Tait RC, Baglin T, Kyrle PA, Cannegieter SC, Rosendaal FR. Sex difference in the risk of recurrent venous thrombosis: a detailed analysis in four European cohorts. *J Thromb Haemost* 2015; 13(10): 1815-22. **5,720**
73. Rumi E, Milosevic JD, Selleslag D, Casetti I, Lierman E, Pietra D, Cavalloni C, Bellini M, Milanese C, Dambrosio I, Astori C, Kralovics R, Vandenberghe P, Cazzola M. Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. *Ann Hematol* 2015; 94(11): 1927-8. *Letter to the Editor* **2,634**
74. Schellongowski P, Riss K, Staudinger T, Ullrich R, Krenn CG, Sitzwohl C, Bojic A, Wohlfarth P, Sperr WR, Rabitsch W, Aigner C, Taghavi S, Jaksch P, Klepetko W, Lang G. Extracorporeal CO<sub>2</sub> removal as bridge to lung transplantation in life-threatening hypercapnia. *Transpl Int* 2015; 28(3): 297-304. **2,599**



75. Schiefer AI, Kornauth C, Simonitsch-Klupp I, Skrabs C, Masel EK, Streubel B, Vanura K, Walter K, Migschitz B, Stoiber D, Sexl V, Raderer M, Chott A, da Silva MG, Cabecadas J, Müllauer L, Jäger U, Porpaczy E. Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study. *Medicine (Baltimore)* 2015; 94(52): e2388. **5,723**
76. Schulenburg A, Blatt K, Cerny-Reiterer S, Sadovnik I, Herrmann H, Marian B, Grunt TW, Zielinski CC, Valent P. Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? *J Hematol Oncol* 2015; 8: 16. *Review* **4,812**
77. Schwameis M, Schober A, Schörghenhofer C, Sperr WR, Schöchl H, Janata-Schwartzek K, Kürkcian EI, Sterz F, Jilma B. Asphyxia by Drowning Induces Massive Bleeding Due To Hyperfibrinolytic Disseminated Intravascular Coagulation. *Crit Care Med* 2015; 43(11): 2394-402. **6,312**
78. Selleslag D, Bird R, Altomare I, Giagounidis A, Janssens A, Pabinger I, Pullarkat V, Wei H, Kreuzbauer G. Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider. *Eur J Haematol* 2015; 94(2): 169-76. **2,066**
79. Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K, Leung W, Godfrey AL, Guglielmelli P, Callaway A, Ward D, Aranaz P, White HE, Waghorn K, Lin F, Chase A, Baxter EJ, Maclean C, Nangalia J, Chen E, Evans P, Short M, Jack A, Wallis L, Oscier D, Duncombe AS, Schuh A, Mead AJ, Griffiths M, Ewing J, Gale RE, Schnittger S, Haferlach T, Stegelmann F, Döhner K, Grallert H, Strauch K, Tanaka T, Bandinelli S, Giannopoulos A, Pieri L, Mannarelli C, Gisslinger H, Barosi G, Cazzola M, Reiter A, Harrison C, Campbell P, Green AR, Vannucchi A, Cross NC. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. *Nat Commun* 2015; 6: 6691. **11,470**
80. Thaler J, Pabinger I, Ay C. Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art. *Front Cardiovasc Med* 2015; 2: 30. *Review* -
81. Them NC, Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Zagrijtschuk O, Klade C, Greil R, Gisslinger H, Kralovics R. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. *Am J Hematol* 2015; 90(4): 288-94. **3,798**
82. Theoharides TC, Valent P, Akin C. Mast Cells, Mastocytosis, and Related Disorders. *N Engl J Med* 2015; 373(19): 1885-6. *Correspondence* **55,873**
83. Theoharides TC, Valent P, Akin C. Mast Cells, Mastocytosis, and Related Disorders. *N Engl J Med* 2015; 373(2): 163-72. *Review* **55,873**

84. Tiede A, Klamroth R, Scharf RE, Trappe RU, Holstein K, Huth-Kühne A, Gottstein S, Geisen U, Schenk J, Scholz U, Schilling K, Neumeister P, Miesbach W, Manner D, Greil R, von Auer C, Krause M, Leimkühler K, Kalus U, Blumtritt JM, Werwitzke S, Budde E, Koch A, Knöbl P. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. *Blood* 2015; 125(7): 1091-7. **10,452**
85. Valent P, Berger J, Cerny-Reiterer S, Peter B, Eisenwort G, Hoermann G, Müllauer L, Mannhalter C, Steurer M, Bettelheim P, Horny HP, Arock M. Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. *Ann Hematol* 2015; 94(2): 223-31. **2,634**
86. Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. *Blood* 2015; 125(6): 901-6. **10,452**
87. Valent P, Sotlar K, Sperr WR, Reiter A, Arock M, Horny HP. Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features. *Leuk Res* 2015; 39(1): 1-5. *Review* **2,351**
88. Valent P. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology. *Hematology Am Soc Hematol Educ Program* 2015; 2015(1): 98-105. **3,137**
89. van Es N, Di Nisio M, Bleker SM, Segers A, Mercuri MF, Schwocho L, Kakkar A, Weitz JI, Beyer-Westendorf J, Boda Z, Carrier M, Chlumsky J, Décousus H, Garcia D, Gibbs H, Kamphuisen PW, Monreal M, Ockelford P, Pabinger I, Verhamme P, Grosso MA, Büller HR, Raskob GE. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. *Thromb Haemost* 2015; 114(6): 1268-76. **4,984**
90. Vannucchi AM, Kantarjian HM, Kiladjan JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovska V, Gupta V, Harrison C, Verstovsek S; COMFORT Investigators (Gisslinger H). A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. *Haematologica* 2015; 100(9): 1139-45. **5,814**
91. Veigel D, Wagner R, Stübiger G, Wuczkowski M, Filipits M, Horvat R, Benhamú B, López-Rodríguez ML, Leisser A, Valent P, Grusch M, Hegardt FG, García J, Serra D, Auersperg N, Colomer R, Grunt TW. Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells. *Int J Cancer* 2015; 136(9): 2078-90. **5,085**
92. Wedeh G, Cerny-Reiterer S, Eisenwort G, Herrmann H, Blatt K, Hadzijusufovic E, Sadvnik I, Müllauer L, Schwaab J, Hoffmann T, Bradner JE, Radia D, Sperr WR, Hoermann G, Reiter A, Horny HP, Zuber J, Arock M, Valent P. Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia. *Leukemia* 2015; 29(11): 2230-7. **10,431**

93. Wiechers T, Rabenhorst A, Schick T, Preussner LM, Förster A, Valent P, Horny HP, Sotlar K, Hartmann K. Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis. *J Allergy Clin Immunol* 2015; 136(6): 1581-1590. **11,476**
94. Ye M, Zhang H, Yang H, Koche R, Staber PB, Cusan M, Levantini E, Welner RS, Bach CS, Zhang J, Krivtsov AV, Armstrong SA, Tenen DG. Hematopoietic Differentiation Is Required for Initiation of Acute Myeloid Leukemia. *Cell Stem Cell* 2015; 17(5): 611-23. **22,268**

**INSGESAMT**

**670,662**